The SentiMag® is revolutionising the sentinel node biopsy procedure by removing the reliance on problematic radioactive isotopes.
Following safe and proven medical practice, Sienna+® is injected near the tumour to provide a trackable signal. The SentiMag® is then used by surgeons to locate the lymph node or nodes closest to the tumour – a vital step to determining whether or how far the cancer has spread.
SentiMag® offers ultrasensitive detection and location of sentinel lymph nodes with unprecedented discrimination. The system is suitable for both pre- and post-incision use, and it represents an effective and valuable alternative to nuclear medicine for node detection enabling the latest medical practice to be offered in a greater variety of hospitals.
The SentiMag® is CE approved for marketing and sales in Europe. Endomagnetics is currently seeking marketing authorization in other territories to deliver its technology to global markets.